ADOPORT

Brand name authorized in: Spain France Italy United Kingdom

Active ingredients

The drug ADOPORT contains one active pharmaceutical ingredient (API):

1 Tacrolimus
UNII WM0HAQ4WNM - TACROLIMUS

Tacrolimus is a highly potent immunosuppressive agent. In particular, tacrolimus inhibits the formation of cytotoxic lymphocytes, which are mainly responsible for graft rejection. Tacrolimus suppresses T-cell activation and T-helper-cell dependent B-cell proliferation, as well as the formation of lymphokines (such as interleukins-2, -3, and γ-interferon) and the expression of the interleukin-2 receptor.

Read about Tacrolimus

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code
Group title
Classification
L04AD02
Tacrolimus
L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AD Calcineurin inhibitors
Discover more medicines within L04AD02

Medication package inserts

Below package inserts are available for further reading:

Title
Type
Country
ADOPORT Capsule, hard
Summary of Product Characteristics (SPC)
UK

Unique identifiers

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country
Identification scheme
Identifier(s)
ES
Centro de información online de medicamentos de la AEMPS
Identifier(s): 71673, 71674, 71675, 79456
FR
Base de données publique des médicaments
Identifier(s): 61964294, 66927104, 68176916, 68955248
GB
Medicines & Healthcare Products Regulatory Agency
Identifier(s): 180443, 180445, 180447, 180449, 288007, 288010, 299563, 299564
IT
Agenzia Italiana del Farmaco
Identifier(s): 41180062, 41180187, 41180264